New data from Novo Nordisk’s phase 3 trial of an oral ... 46 weeks of treatment with their dual glucagon/GLP1 agonist survodutide (BI 456906) given as a weekly subcutaneous injection resulted ...

Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

$ 81.33 0.23 0.28% ...